Mechanism of checkpoint inhibiting cancer drugs (2016)


Mechanism of checkpoint inhibiting cancer drugs (2016)

This figure illustration describes how atezolizumab, nivolumab, and ipilimumab restore normal T-cell function in exhausted T-cells found in the chronic tumour environment.

Audience: Immunology students, oncology researchers
Tools: Adobe Illustrator


  • Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015). Big opportunities for small molecules in immuno-oncology. Nature Reviews Drug Discovery, 14(9), 603–622.
  • Alegre, M. L., Frauwirth, K. A., & Thompson, C. B. (2001). Figure 3. Schematic representation of the lattic network created by CTLA-4 binding to CD80/86 ligands. Retrieved from
  • Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 14(8), 561–584.

Process work